In a study by Enokida et al., including 177 prostate cancer samples and 69 benign prostate hypertrophy samples, the ABCB1 promoter has been found to be significantly more often methylated in prostate cancer samples than in benign prostate hypertrophy samples [136]. Here, ABCB1 is linked to prostate cancer.